Katharina Wørzner

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 8

Top Topics

Induced Apoptosis

Inflammatory Response

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 9 (1) (2024)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Author Correction: Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 9 (1) (2024)
Julie Zimmermann, Simon Daniel van Haren, Joann Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Diray-Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)
Julie Zimmermann, Simon Daniel van Haren, Joann Arce, Ignatius Ryan Adriawan, Katharina Wørzner, Ricki T Krog, Safia Guleed, Tu Hu, Rasmus Mortensen, Jes Dietrich, Sara M Ø Solbak, Ofer Levy, Dennis Christensen, Gabriel Kristian Pedersen
Co-adjuvanting DDA/TDB liposomes with a TLR7 agonist allows for IgG2a/c class-switching in the absence of Th1 cells. NPJ vaccines 8 (1) (2023)